Peptides in North Carolina: Research, Regulation and Where the Law Stands

Searches for "peptides North Carolina" usually mix several different questions together: whether a peptide is an approved medicine, what "research use only" labelling means, how compounding pharmacies fit in, and who would be responsible for enforcement in the state. Those are separate regulatory layers, and they are answered by different bodies. This page describes the layers and summarises what the published literature reported about peptide drugs. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical or treatment question, and a licensed attorney about any legal question. Nothing here is legal advice and nothing here states whether any particular activity is legal or illegal.

Layer One: Federal Drug Approval

Peptides are not a single legal category. Some are approved drug products with an FDA-reviewed label, a defined indication and a manufacturer subject to inspection. Others have never been submitted for approval and exist only as chemicals sold for laboratory work. A review of the agency's 2017 approvals described how peptide therapeutics moved through the standard new-drug pathway alongside small molecules and biologics, illustrating that peptides as a chemical class are routinely approvable when a sponsor completes the process (PMID 29735913).

The practical consequence is that the phrase "peptide" tells a reader almost nothing about regulatory status. Semaglutide and tirzepatide are approved prescription products with post-marketing surveillance systems attached to them. Many other peptides discussed online — particularly those marketed around musculoskeletal repair or athletic performance — have no approval at all. A 2026 review in Sports Medicine examined approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance and reported that the evidence base for the unapproved compounds was substantially weaker than for approved products, with limited controlled human data (PMID 41966639).

Layer Two: "Research Use Only" Supply

Material sold with a "research use only" (RUO) or "not for human consumption" label is not a regulated drug product. It has no FDA-reviewed label, no approved indication, and no requirement to meet the identity, purity, sterility and potency standards that apply to finished pharmaceuticals. RUO labelling is a statement about the intended market, not a certification of quality.

Analytical work on peptide quality has shown why that distinction matters. A 2024 pharmaceutical sciences study compared manufacturing and compounding processes for follow-on GLP-1 polypeptide drugs and reported measurable differences in product properties and quality attributes depending on how the material was produced (PMID 39379664). That analysis concerned pharmaceutical-grade and compounded material — a category already more controlled than RUO chemicals.

Layer Three: Compounding and the 503A/503B Distinction

Compounding sits between approval and unregulated supply, and it is where much of the recent peptide conversation has landed. Two federal sections define it:

Neither route produces an FDA-approved drug. Both depend on the underlying active ingredient being eligible for compounding under federal rules, which change when a drug moves on or off the agency's shortage list or when a substance is placed on lists restricting compounding. Those determinations are federal and apply in North Carolina exactly as they apply elsewhere.

Clinical data on compounded peptide products remain thin. One 2025 real-world analysis followed patients treated with compounded semaglutide and reported weight loss and body-composition changes in that setting (PMID 39776038). Researchers described it as an observational real-world cohort rather than a randomised comparison against the approved product.

What Is Specific to North Carolina

North Carolina does not have a peptide-specific statute that singles the class out. What the state does have is the ordinary architecture of professional licensing, and that architecture is where state-level authority sits:

• North Carolina Board of Pharmacy. Licenses pharmacies and pharmacists operating in or shipping into the state, including out-of-state pharmacies that dispense to North Carolina residents. Compounding practice by a 503A pharmacy falls within its inspection and disciplinary remit.
• North Carolina Medical Board. Licenses physicians and physician assistants and governs the standard of care, recordkeeping, and the conduct of the prescriber–patient relationship, including when that relationship is established or maintained by telehealth.
• North Carolina statutes on controlled substances and food and drug regulation. These mirror federal structures in broad terms; most peptides discussed in consumer contexts are not scheduled controlled substances, which means the relevant questions are usually about drug approval, compounding and licensure rather than scheduling.

Where a specific North Carolina rule on peptides is not verifiable from a primary state source, this page says so plainly rather than filling the gap: no North Carolina-specific peptide statute or board rule naming peptides as a distinct class has been identified for this page. Readers looking for the current position should consult the Board of Pharmacy, the Medical Board, or a licensed North Carolina attorney directly, because board rules and position statements are updated on their own schedules.

Telehealth Prescribing

Much peptide prescribing now happens through telehealth platforms that operate nationally. The governing principle is that the prescriber must generally hold a licence in the state where the patient is located, and that the state medical board sets the standard for how a valid clinician–patient relationship is established remotely. Interstate platforms therefore do not escape North Carolina oversight simply by being headquartered elsewhere; the patient's location is what draws the state's licensing authority in.

Adverse Events in Approved Peptide Drugs: What Studies Report

Regulatory oversight exists in part because of what post-marketing surveillance has found. Pharmacovigilance databases collect spontaneous reports; they establish signals and disproportionality, not causation or incidence rates.

Gastrointestinal signals

A disproportionality analysis of the FDA Adverse Event Reporting System examined gastrointestinal reports associated with semaglutide and reported signals for nausea, vomiting, diarrhoea and constipation (PMID 36339230). A separate FAERS study compared GLP-1 receptor agonists as a class and reported that gastrointestinal adverse reactions differed in reporting pattern between agents (PMID 36568085). A further post-marketing analysis of semaglutide described the broader real-world reporting profile across organ systems (PMID 38943656).

Pancreatitis and metabolic signals

Researchers combined a case series with real-world pharmacovigilance analysis and reported an association signal between GLP-1 receptor agonists and acute pancreatitis (PMID 39605914). Another pharmacovigilance study of the same class focused on metabolic and nutritional adverse events and reported disproportionate reporting in that category (PMID 39040467).

Psychiatric signals

An analysis of individual case safety reports in EudraVigilance examined psychiatric adverse events reported with semaglutide, liraglutide and tirzepatide (PMID 38265519). A FAERS-based study explored the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviours and described the limitations of drawing causal conclusions from spontaneous reports (PMID 38355513).

Tirzepatide

A dedicated FAERS analysis characterised the real-world safety profile of tirzepatide and reported the adverse-event categories most frequently submitted for that agent (PMID 39141075).

None of these studies reported findings for RUO peptides sold outside the drug supply chain, because such material generates no systematic adverse-event reporting at all. That absence of data is a structural feature of the unregulated market, not evidence of safety.

How the Layers Interact

1. Federal approval determines whether a finished product exists as a lawful medicine with a reviewed label.
2. Federal compounding law determines whether a pharmacy or outsourcing facility may prepare a version, and under which standards.
3. North Carolina licensure determines who may prescribe, dispense and operate within the state, and who investigates when practice standards are questioned.
4. RUO supply sits outside all three, which is precisely why it carries no quality guarantee and no surveillance record.

A reader trying to understand a specific situation in North Carolina generally needs to identify which of these layers the question actually belongs to. Questions about product quality are federal; questions about a particular pharmacy or prescriber are usually state.

Limitations of the Evidence Described Here

Every safety study cited on this page draws on spontaneous reporting systems, which are subject to under-reporting, duplicate reports, reporting bias driven by media attention, and missing denominators. Disproportionality signals indicate that a combination was reported more often than expected within a database — not that a drug caused an outcome at a given rate. The compounded-semaglutide cohort was observational (PMID 39776038), and the musculoskeletal peptide review repeatedly noted the scarcity of controlled human trials for unapproved compounds (PMID 41966639).

Again: this page is educational, describes regulatory structure and published findings, and does not state or imply that any activity in North Carolina is permitted or prohibited. Legal questions belong with a licensed attorney; clinical questions belong with a licensed physician.

References

• 2017 FDA Peptide Harvest (Pharmaceuticals, 2018)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)
• Weight loss and body composition after compounded semaglutide treatment in a real world setting (Diabetes, Obesity & Metabolism, 2025)
• Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (Frontiers in Public Health, 2022)
• Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database (Frontiers in Endocrinology, 2022)
• A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data (Journal of Diabetes Investigation, 2024)
• Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis (Frontiers in Pharmacology, 2024)
• Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events (Frontiers in Pharmacology, 2024)
• Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database (International Journal of Clinical Pharmacy, 2024)
• Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database (BMC Medicine, 2024)
• The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (Journal of Endocrinological Investigation, 2024)